ZA200804237B - Fused bicyclic mTOR inhibitors - Google Patents

Fused bicyclic mTOR inhibitors

Info

Publication number: ZA200804237B
Authority: ZA; South Africa
Prior art keywords: fused bicyclic; mtor inhibitors; bicyclic mtor; inhibitors; fused
Prior art date: 2005-11-17

Application number

ZA200804237A

Other languages

English (en)

Inventor

Honda Ayako

Lee D Arnold

Chen Xin

Coate Heather

Crew Andrew-Phillip

Dong Han-Qing

Beard James David

Mulvihill Mark Joseph

Paula A R Tavares

Wang Jing

Douglas S Werner

Mulvihill Kristen Michelle

Kam W Siu

Panicker Bijoy

Bharadwaj Apoorba

Volk Brian

Jin Meizhong

Weng Qinghua

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-17

Filing date

2008-05-16

Publication date

2009-09-30

2008-05-16 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2009-09-30 Publication of ZA200804237B publication Critical patent/ZA200804237B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200804237A 2005-11-17 2008-05-16 Fused bicyclic mTOR inhibitors ZA200804237B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73758105P	2005-11-17	2005-11-17
US85424706P	2006-10-25	2006-10-25

Publications (1)

Publication Number	Publication Date
ZA200804237B true ZA200804237B (en)	2009-09-30

Family

ID=38066461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200804237A ZA200804237B (en)	2005-11-17	2008-05-16	Fused bicyclic mTOR inhibitors

Country Status (25)

Country	Link
US (6)	US7700594B2 (xx)
EP (3)	EP1951724B1 (xx)
JP (2)	JP5335432B2 (xx)
KR (1)	KR20080078668A (xx)
CN (2)	CN101316845A (xx)
AR (1)	AR056884A1 (xx)
AT (1)	ATE507227T1 (xx)
AU (1)	AU2006316605B2 (xx)
BR (1)	BRPI0618622A2 (xx)
CA (1)	CA2630271C (xx)
DE (1)	DE602006021608D1 (xx)
DK (1)	DK1951724T3 (xx)
EA (1)	EA015463B1 (xx)
ES (2)	ES2365869T3 (xx)
HR (1)	HRP20110553T1 (xx)
IL (1)	IL191532A0 (xx)
MY (1)	MY148491A (xx)
NZ (1)	NZ569050A (xx)
PL (2)	PL1951724T3 (xx)
PT (2)	PT2385053E (xx)
RS (1)	RS51843B (xx)
SI (1)	SI1951724T1 (xx)
TW (1)	TWI382028B (xx)
WO (1)	WO2007061737A2 (xx)
ZA (1)	ZA200804237B (xx)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602005014964D1 (de)	2004-04-02	2009-07-30	Osi Pharm Inc	Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
JP2008520744A (ja)	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
CA2605778A1 (en) *	2005-04-20	2006-10-26	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
PT2385053E (pt)	2005-11-17	2013-12-17	Osi Pharm Inc	Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
AR057960A1 (es) *	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
TW201307354A (zh) *	2005-12-29	2013-02-16	Abbott Lab	蛋白質激酶抑制劑
US7659274B2 (en) *	2006-01-25	2010-02-09	Osi Pharmaceuticals, Inc.	Unsaturated mTOR inhibitors
WO2007106503A2 (en) *	2006-03-13	2007-09-20	Osi Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
KR20130087054A (ko)	2006-04-04	2013-08-05	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
US8124759B2 (en)	2007-05-09	2012-02-28	Abbott Laboratories	Inhibitors of protein kinases
WO2008141140A1 (en) *	2007-05-09	2008-11-20	Abbott Laboratories	Condensed heterocyclic compounds as inhibitors of protein kinases
CA2685351A1 (en) *	2007-05-09	2008-11-20	Abbott Laboratories	Inhibitors of protein kinases
WO2008148074A2 (en) *	2007-05-24	2008-12-04	Research Foundation Of State University Of New York	Inhibitors of mtor and methods of treatment using same
JP2010532756A (ja) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
MX358640B (es)	2008-01-04	2018-08-29	Intellikine Llc	Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP2011510018A (ja) *	2008-01-18	2011-03-31	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	癌治療のためのイミダゾピラジノール誘導体
CN101981036B (zh) *	2008-02-06	2013-09-04	诺瓦提斯公司	吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
WO2009111547A1 (en) *	2008-03-04	2009-09-11	Wyeth	7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US20100048914A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP5547099B2 (ja) *	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
CA2716924A1 (en) *	2008-03-19	2009-09-24	Osi Pharmaceuticals, Inc.	Mtor inhibitor salt forms
AU2009225434B2 (en)	2008-03-21	2014-05-22	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
EP2283020B8 (en) *	2008-05-19	2012-12-12	OSI Pharmaceuticals, LLC	Substituted imidazopyr-and imidazotri-azines
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
US9096611B2 (en) *	2008-07-08	2015-08-04	Intellikine Llc	Kinase inhibitors and methods of use
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
JP5819195B2 (ja)	2008-10-16	2015-11-18	ザリージェンツオブザユニバーシティオブカリフォルニア	融合環ヘテロアリールキナーゼ阻害剤
US8110578B2 (en) *	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CN102325753B (zh)	2008-12-19	2014-09-10	百时美施贵宝公司	用作激酶抑制剂的咔唑甲酰胺化合物
EP3023433A1 (en)	2009-02-05	2016-05-25	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010118207A1 (en) *	2009-04-09	2010-10-14	Schering Corporation	Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
EP2421837A1 (en)	2009-04-20	2012-02-29	OSI Pharmaceuticals, LLC	Preparation of c-pyrazine-methylamines
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
JP2012526138A (ja) *	2009-05-07	2012-10-25	オーエスアイ・ファーマシューティカルズ，エルエルシー	副腎皮質癌を治療するためのｏｓｉ−９０６の使用
US20120108812A1 (en) *	2009-07-09	2012-05-03	Osi Pharmaceuticals ,Inc.	Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines
HRP20190016T1 (hr)	2009-08-17	2019-03-08	Intellikine, Llc	Heterociklički spojevi i njihova upotreba
WO2011041152A1 (en)	2009-09-30	2011-04-07	Schering Corporation	Novel compounds that are erk inhibitors
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
EP2526102B1 (en)	2010-01-22	2017-03-08	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Inhibitors of PI3 kinase
EP2528919B1 (en) *	2010-01-28	2016-11-02	University of Washington	Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en)	2010-01-28	2017-09-19	University Of Washington Through Its Center For Commercialization	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
UA110697C2 (uk)	2010-02-03	2016-02-10	Сігнал Фармасьютікалз, Елелсі	ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
WO2011112666A1 (en)	2010-03-09	2011-09-15	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2011111051A1 (en)	2010-03-11	2011-09-15	Yeda Research And Development Co. Ltd.	Death associated protein 1 variants and use thereof for modulating autophagy
US20130035336A1 (en)	2010-04-13	2013-02-07	Novartis Ag	Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
US20130131057A1 (en) *	2010-05-13	2013-05-23	Centro Nacional De Investigaciones Oncologicas (Cnio	New bicyclic compounds as pi3-k and mtor inhibitors
EP2571357B1 (en)	2010-05-21	2016-07-06	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
US20120028972A1 (en) *	2010-07-30	2012-02-02	Lilly Wong	Biomarker assays for detecting or measuring inhibition of tor kinase activity
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
CN103298474B (zh)	2010-11-10	2016-06-29	无限药品股份有限公司	杂环化合物及其用途
TWI546305B (zh)	2011-01-10	2016-08-21	英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
EP2678018A4 (en)	2011-02-23	2015-09-30	Intellikine Llc	COMBINATION OF CHINESE HEMMER AND USES THEREOF
AP2013007070A0 (en)	2011-02-23	2013-08-31	Pfizer	Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
AU2012284088B2 (en)	2011-07-19	2015-10-08	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
WO2013012918A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP3495368B1 (en)	2011-07-19	2023-05-31	Merck Sharp & Dohme B.V.	(s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
EP2734523A1 (en) *	2011-07-19	2014-05-28	Merck Sharp & Dohme B.V.	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP2739751A1 (en)	2011-08-03	2014-06-11	Signal Pharmaceuticals, LLC	Identification of gene expression profile as a predictive biomarker for lkb1 status
CA2846431A1 (en)	2011-08-29	2013-03-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP2791143B1 (en) *	2011-12-15	2016-02-24	Bayer Intellectual Property GmbH	Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
UY34484A (es) *	2011-12-15	2013-07-31	Bayer Ip Gmbh	Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2865021C (en)	2012-02-23	2020-06-30	Bayer Intellectual Property Gmbh	Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2013152342A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN103374001B (zh) *	2012-04-19	2015-10-28	山东轩竹医药科技有限公司	咪唑并三嗪类mTOR抑制剂
CN103374021B (zh) *	2012-04-21	2015-10-28	通化济达医药有限公司	含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru)	2012-09-26	2016-11-20	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Модулирование ire1
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105102000B (zh)	2012-11-01	2021-10-22	无限药品公司	使用pi3激酶亚型调节剂的癌症疗法
KR20150127720A (ko)	2013-03-14	2015-11-17	유니버시티 오브 매릴랜드, 발티모어	안드로겐 수용체 하향 조절제 및 그의 용도
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9724354B2 (en)	2013-03-22	2017-08-08	Millennium Pharmaceuticals, Inc.	Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
MX368286B (es)	2013-04-17	2019-09-27	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
NZ629411A (en)	2013-04-17	2017-06-30	Signal Pharm Llc	Treatment of cancer with dihydropyrazino-pyrazines
KR102242505B1 (ko)	2013-04-17	2021-04-20	시그날 파마소티칼 엘엘씨	암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
AU2014254057A1 (en)	2013-04-17	2015-11-05	Signal Pharmaceuticals, Llc	Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
BR112015026257B1 (pt)	2013-04-17	2022-12-20	Signal Pharmaceuticals, Llc	Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
SG11201508527VA (en)	2013-04-17	2015-11-27	Signal Pharm Llc	Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
ES2944478T3 (es)	2013-04-17	2023-06-21	Signal Pharm Llc	1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
CA2913035C (en)	2013-05-20	2017-08-01	University Of Washington Through Its Center For Commercialization	5-aminopyrazole-4-carboxamide inhibitors of cdpk1
JP6401250B2 (ja)	2013-05-29	2018-10-10	シグナルファーマシューティカルズ，エルエルシー	７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
CA2928568A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015023710A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
EP3076974A1 (en)	2013-12-05	2016-10-12	Acerta Pharma B.V.	Therapeutic combination of a pi3k inhibitor and a btk inhibitor
EP3094314B1 (en)	2014-01-16	2021-06-23	MUSC Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
JP6855243B2 (ja)	2014-01-24	2021-04-07	エイアイ・セラピューティクス・インコーポレーテッド	癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
EA201691872A1 (ru)	2014-03-19	2017-04-28	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
US9937171B2 (en)	2014-04-11	2018-04-10	Acerta Pharma B.V.	Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en)	2014-04-16	2016-12-06	Signal Pharmaceuticals, Llc	Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
MX2016015569A (es)	2014-06-02	2017-04-25	Children´S Medical Center Corp	Metodos y composiciones para inmunomodulacion.
CA2951259A1 (en)	2014-06-06	2015-12-10	Flexus Biosciences, Inc.	Immunoregulatory agents
TW201613644A (en)	2014-06-17	2016-04-16	Acerta Pharma Bv	Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
TW201618772A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
ES2807785T3 (es)	2014-10-22	2021-02-24	Bristol Myers Squibb Co	Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
US10023576B2 (en)	2014-10-22	2018-07-17	Bristol-Myers Squibb Company	Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) *	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
WO2016073738A2 (en)	2014-11-05	2016-05-12	Flexus Biosciences, Inc.	Immunoregulatory agents
KR20170098812A (ko)	2014-11-07	2017-08-30	램 테라퓨틱스, 인코포레이티드	신장암의 치료에 사용하기 위한 아필리모드
US20190209576A1 (en)	2014-11-07	2019-07-11	AI Therapeutics, Inc.	Apilimod for use in the treatment of colorectal cancer
CA2967125C (en) *	2014-11-14	2022-10-25	Nerviano Medical Sciences S.R.L.	6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
WO2016106623A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Benzamide imidazopyrazine btk inhibitors
KR20170118687A (ko)	2015-02-19	2017-10-25	제이엔씨 주식회사	벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
US20180078561A1 (en)	2015-03-31	2018-03-22	Lam Therapeutics, Inc.	Active metabolites of apilimod and uses thereof
US9840503B2 (en)	2015-05-11	2017-12-12	Incyte Corporation	Heterocyclic compounds and uses thereof
SI3317281T1 (sl)	2015-07-02	2020-08-31	Acerta Pharma B.V.	Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida
WO2017027717A1 (en)	2015-08-12	2017-02-16	Incyte Corporation	Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en)	2015-08-26	2018-08-21	Incyte Corporation	Pyrrolopyrimidine derivatives as TAM inhibitors
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN105732460A (zh) *	2016-02-03	2016-07-06	常州工程职业技术学院	一种吲哚类化合物的合成方法
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017172596A1 (en) *	2016-03-28	2017-10-05	Incyte Corporation	Pyrrolotriazine compounds as tam inhibitors
SG11201808878UA (en)	2016-04-15	2018-11-29	Cancer Research Tech Ltd	Heterocyclic compounds as ret kinase inhibitors
EP3442535B1 (en)	2016-04-15	2022-06-01	Cancer Research Technology Limited	Heterocyclic compounds as ret kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3474856B1 (en)	2016-06-24	2022-09-14	Infinity Pharmaceuticals, Inc.	Combination therapies
GB201705971D0 (en)	2017-04-13	2017-05-31	Cancer Res Tech Ltd	Inhibitor compounds
IL303660A (en) *	2017-05-02	2023-08-01	Revolution Medicines Inc	Rapamycin analogs as mtor inhibitors
EP3641772B1 (en)	2017-06-22	2023-08-02	Celgene Corporation	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
JP7341122B2 (ja) *	2017-08-15	2023-09-08	石薬集団中奇制薬技術（石家庄）有限公司	Ｆｇｆｒ阻害剤及びその医薬品の用途
CA3077308A1 (en)	2017-09-27	2019-04-04	Incyte Corporation	Salts of pyrrolotriazine derivatives useful as tam inhibitors
CA3076915A1 (en)	2017-09-27	2019-04-04	AI Therapeutics, Inc.	Therapeutic methods relating to hsp90 inhibitors
FR3075794A1 (fr)	2017-12-21	2019-06-28	Galderma Research & Development	Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) *	2017-12-21	2019-06-28	Galderma Research & Development	Nouveaux composes inhibiteurs de mtor
MX2020007531A (es) *	2018-01-26	2020-09-09	Bristol Myers Squibb Co	Aminopirrolotriazinas como inhibidores de cinasa.
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
MA52422A (fr)	2018-02-27	2021-01-06	Incyte Corp	Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
CA3098692A1 (en)	2018-05-01	2019-11-07	Revolution Medicines, Inc.	C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2019212991A1 (en)	2018-05-01	2019-11-07	Revolution Medicines, Inc.	C26-linked rapamycin analogs as mtor inhibitors
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
EP3801069A4 (en)	2018-06-01	2022-03-16	Cornell University	MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
SG11202012447YA (en)	2018-06-15	2021-01-28	Navitor Pharm Inc	Rapamycin analogs and uses thereof
PL3813800T3 (pl)	2018-06-29	2025-08-18	Incyte Corporation	Formulacje inhibitora axl/mer
MA53097A (fr)	2018-07-05	2021-05-12	Incyte Corp	Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
CA3111980A1 (en)	2018-09-10	2020-03-19	Mirati Therapeutics, Inc.	Combination therapies
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12021551812A1 (en) *	2019-01-31	2022-03-21	Bayer Ag	The monohydrate of rogaratinib hydrochloride and solid states thereof
TW202134234A (zh)	2019-12-05	2021-09-16	美商奈維特製藥公司	雷帕黴素類似物及其用途
AU2021230385A1 (en)	2020-03-06	2022-09-22	Incyte Corporation	Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
MX2023009417A (es)	2021-02-16	2023-12-01	Vaccitech North America Inc	Nanopartículas de autoensamblaje basadas en péptidos anfifílicos.
WO2023288046A1 (en)	2021-07-15	2023-01-19	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
AU2023275778A1 (en)	2022-05-25	2024-12-12	Revolution Medicines, Inc.	Methods of treating cancer with an mtor inhibitor
IL320235A (en)	2022-10-25	2025-06-01	Barinthus Biotherapeutics North America Inc	Self-assembled nanoparticles
CN118754873B (zh) *	2024-06-27	2025-03-07	广东医科大学	一种环丁烷吲哚衍生物及其制备方法和应用
CN118994167B (zh) *	2024-08-09	2025-09-12	南京健康产业研究院	一种咪唑并[1,5-a]吡嗪类抗肿瘤化合物及其制备方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE791025A (fr) *	1971-11-19	1973-05-07	Allen & Hanburys Ltd	Composes heterocycliques
NZ293249A (en)	1994-09-29	1999-04-29	Novartis Ag	4-amino-5,7-diaryl-pyrrolo[2,3-d]pyrimidines and their use
US6071891A (en) *	1996-11-22	2000-06-06	Regents Of The University Of Minnesota	Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
CA2283961A1 (en)	1997-03-19	1998-09-24	Basf Aktiengesellschaft	Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
DE1140938T1 (de)	1999-01-11	2003-01-09	Princeton University, Princeton	Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
SK3792002A3 (en)	1999-09-17	2003-09-11	Abbott Gmbh & Co Kg	Kinase inhibitors as therapeutic agents
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
PT1212327E (pt)	1999-09-17	2004-01-30	Abbott Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1425284A2 (en)	2001-09-11	2004-06-09	Smithkline Beecham Corporation	Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
TW200306819A (en)	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
US20040209930A1 (en) *	2002-10-02	2004-10-21	Carboni Joan M.	Synergistic methods and compositions for treating cancer
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
WO2004074448A2 (en)	2003-02-18	2004-09-02	Whitehead Institute For Biomedical Research	mTOR KINASE-ASSOCIATED PROTEINS
KR100872204B1 (ko)	2003-10-15	2008-12-09	오에스아이 파마슈티컬스, 인코포레이티드	이미다조피라진 티로신 키나제 억제제
WO2005044835A1 (en)	2003-10-27	2005-05-19	Genelabs Technologies, Inc.	METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
EP1687321A1 (en)	2003-10-27	2006-08-09	Genelabs Technologies, Inc.	Nucleoside compounds for treating viral infections
JP2007511596A (ja)	2003-11-17	2007-05-10	ファイザー・プロダクツ・インク	癌の治療において有用なピロロピリミジン化合物
EP1694686A1 (en) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
DE602005014964D1 (de) *	2004-04-02	2009-07-30	Osi Pharm Inc	Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
BRPI0513200A (pt) *	2004-07-16	2008-04-29	Pfizer Prod Inc	uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
TW200613306A (en) *	2004-07-20	2006-05-01	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
JP2008520744A (ja) *	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
US7906308B2 (en)	2005-01-28	2011-03-15	Whitehead Institute For Biomedical Research	Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
EP1946120A2 (en)	2005-10-18	2008-07-23	George Mason Intellectual Properties, Inc.	Mtor pathway theranostic
WO2007056170A2 (en) *	2005-11-02	2007-05-18	Bayer Healthcare Ag	Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
PT2385053E (pt)	2005-11-17	2013-12-17	Osi Pharm Inc	Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en)	2005-12-19	2007-07-05	Osi Pharmaceuticals, Inc.	Combination of igfr inhibitor and anti-cancer agent
TW201307354A (zh)	2005-12-29	2013-02-16	Abbott Lab	蛋白質激酶抑制劑
US7659274B2 (en) *	2006-01-25	2010-02-09	Osi Pharmaceuticals, Inc.	Unsaturated mTOR inhibitors
WO2007106503A2 (en) *	2006-03-13	2007-09-20	Osi Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EA200870385A1 (ru)	2006-03-29	2009-04-28	Фолдркс Фармасьютикалз, Инк.	Ингибирование токсичности альфа-синуклеина
KR20130087054A (ko)	2006-04-04	2013-08-05	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
DE102006016426A1 (de)	2006-04-07	2007-10-11	Merck Patent Gmbh	Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
TW200835507A (en)	2006-12-05	2008-09-01	Vioquest Pharmaceuticals Inc	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20090263397A1 (en) *	2007-07-06	2009-10-22	Buck Elizabeth A	Combination anti-cancer therapy
JP2010532756A (ja) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
BRPI0818426A2 (pt)	2007-10-15	2017-06-13	Astrazeneca Ab	produto de combinação, uso de um produto de combinação, e, método para tratar câncer
CA2716924A1 (en) *	2008-03-19	2009-09-24	Osi Pharmaceuticals, Inc.	Mtor inhibitor salt forms
US20120108812A1 (en)	2009-07-09	2012-05-03	Osi Pharmaceuticals ,Inc.	Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines
EP2459191A1 (en)	2009-07-31	2012-06-06	OSI Pharmaceuticals, LLC	Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011112666A1 (en)	2010-03-09	2011-09-15	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy

2006
- 2006-11-15 PT PT111552709T patent/PT2385053E/pt unknown
- 2006-11-15 CN CNA2006800430785A patent/CN101316845A/zh active Pending
- 2006-11-15 NZ NZ569050A patent/NZ569050A/en not_active IP Right Cessation
- 2006-11-15 SI SI200631064T patent/SI1951724T1/sl unknown
- 2006-11-15 CA CA2630271A patent/CA2630271C/en not_active Expired - Fee Related
- 2006-11-15 DE DE602006021608T patent/DE602006021608D1/de active Active
- 2006-11-15 BR BRPI0618622-0A patent/BRPI0618622A2/pt not_active IP Right Cessation
- 2006-11-15 HR HR20110553T patent/HRP20110553T1/hr unknown
- 2006-11-15 KR KR1020087014589A patent/KR20080078668A/ko not_active Ceased
- 2006-11-15 PL PL06837752T patent/PL1951724T3/pl unknown
- 2006-11-15 WO PCT/US2006/044461 patent/WO2007061737A2/en not_active Ceased
- 2006-11-15 EP EP06837752A patent/EP1951724B1/en active Active
- 2006-11-15 EP EP11155270.9A patent/EP2385053B1/en active Active
- 2006-11-15 AU AU2006316605A patent/AU2006316605B2/en not_active Ceased
- 2006-11-15 EA EA200801341A patent/EA015463B1/ru not_active IP Right Cessation
- 2006-11-15 DK DK06837752.2T patent/DK1951724T3/da active
- 2006-11-15 PL PL11155270T patent/PL2385053T3/pl unknown
- 2006-11-15 ES ES06837752T patent/ES2365869T3/es active Active
- 2006-11-15 US US11/599,663 patent/US7700594B2/en active Active
- 2006-11-15 RS RS20110337A patent/RS51843B/sr unknown
- 2006-11-15 PT PT06837752T patent/PT1951724E/pt unknown
- 2006-11-15 JP JP2008541334A patent/JP5335432B2/ja not_active Expired - Fee Related
- 2006-11-15 AT AT06837752T patent/ATE507227T1/de active
- 2006-11-15 CN CN201210369830.2A patent/CN102936250B/zh not_active Expired - Fee Related
- 2006-11-15 ES ES11155270.9T patent/ES2436877T3/es active Active
- 2006-11-15 EP EP11155268.3A patent/EP2325186B1/en active Active
- 2006-11-15 MY MYPI20081660A patent/MY148491A/en unknown
- 2006-11-16 TW TW095142464A patent/TWI382028B/zh not_active IP Right Cessation
- 2006-11-17 AR ARP060105058A patent/AR056884A1/es not_active Application Discontinuation
2008
- 2008-05-16 ZA ZA200804237A patent/ZA200804237B/xx unknown
- 2008-05-18 IL IL191532A patent/IL191532A0/en unknown
- 2008-12-02 US US12/326,536 patent/US7923555B2/en active Active
2009
- 2009-11-09 JP JP2009255728A patent/JP4491510B2/ja not_active Expired - Fee Related
- 2009-11-20 US US12/622,545 patent/US7943767B2/en active Active
2011
- 2011-04-13 US US13/085,722 patent/US20110190496A1/en not_active Abandoned
- 2011-05-13 US US13/106,954 patent/US8314111B2/en active Active
2013
- 2013-02-15 US US13/767,947 patent/US8796455B2/en active Active

Also Published As

Publication number	Publication date
US8314111B2 (en)	2012-11-20
EP2385053B1 (en)	2013-10-02
EP2325186A3 (en)	2011-10-26
JP2010065049A (ja)	2010-03-25
US7923555B2 (en)	2011-04-12
WO2007061737A2 (en)	2007-05-31
TWI382028B (zh)	2013-01-11
PT2385053E (pt)	2013-12-17
CN102936250B (zh)	2014-07-09
CA2630271A1 (en)	2007-05-31
EP2325186B1 (en)	2014-10-08
HK1121158A1 (en)	2009-04-17
PT1951724E (pt)	2011-08-02
ES2365869T3 (es)	2011-10-11
CA2630271C (en)	2014-04-08
DK1951724T3 (da)	2011-08-15
KR20080078668A (ko)	2008-08-27
EP2385053A3 (en)	2012-02-29
US20070112005A1 (en)	2007-05-17
US20110218183A1 (en)	2011-09-08
PL1951724T3 (pl)	2011-09-30
SI1951724T1 (sl)	2011-09-30
US7943767B2 (en)	2011-05-17
AU2006316605B2 (en)	2012-04-26
NZ569050A (en)	2010-11-26
AU2006316605A1 (en)	2007-05-31
TW200801006A (en)	2008-01-01
AR056884A1 (es)	2007-10-31
RS51843B (sr)	2012-02-29
CN101316845A (zh)	2008-12-03
US20090163468A1 (en)	2009-06-25
IL191532A0 (en)	2008-12-29
MY148491A (en)	2013-04-30
EA200801341A1 (ru)	2008-12-30
US20100099679A1 (en)	2010-04-22
PL2385053T3 (pl)	2014-05-30
EP2325186A2 (en)	2011-05-25
ES2436877T3 (es)	2014-01-07
US8796455B2 (en)	2014-08-05
CN102936250A (zh)	2013-02-20
EP2385053A2 (en)	2011-11-09
EP1951724B1 (en)	2011-04-27
EA015463B1 (ru)	2011-08-30
ATE507227T1 (de)	2011-05-15
US7700594B2 (en)	2010-04-20
BRPI0618622A2 (pt)	2011-09-06
US20130165651A1 (en)	2013-06-27
WO2007061737A3 (en)	2007-12-06
DE602006021608D1 (de)	2011-06-09
US20110190496A1 (en)	2011-08-04
JP5335432B2 (ja)	2013-11-06
JP4491510B2 (ja)	2010-06-30
JP2009519222A (ja)	2009-05-14
EP1951724A2 (en)	2008-08-06
HRP20110553T1 (hr)	2011-09-30

Publication	Publication Date	Title
ZA200804237B (en)	2009-09-30	Fused bicyclic mTOR inhibitors
IL196207A0 (en)	2009-09-22	Fused pyrimido compounds
IL181848A0 (en)	2007-07-04	Substituted bicyclic imidazo-3-yl-amine compounds
EP1928237A4 (en)	2011-03-09	NEW HETEROCYCLES BASED ON IMIDAZO
IL239445A0 (en)	2015-07-30	Bicyclic heteroaryl compounds
IL226486A0 (en)	2013-06-27	Converted pyrazolopyrimidine compounds
ZA200803811B (en)	2009-08-26	Neuropolin antagonists
ZA200709871B (en)	2008-11-26	Interferon-IgG fusion
IL186407A0 (en)	2008-01-20	Fused heterocyclic compounds
SI1973545T1 (sl)	2013-04-30	Spojine bicikličnega heteroarila
ZA200804335B (en)	2010-05-26	Substituted bicyclic pyrimidone derivatives
ZA200804104B (en)	2009-11-25	Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
EP1961754A4 (en)	2009-11-11	BICYCLIC HETEROCYCLIC COMPOUND
GB0518232D0 (en)	2005-10-19	New methods
ZA200708844B (en)	2009-08-26	Fused heterocyclic compounds
GB0404801D0 (en)	2004-04-07	Bicyclic derivatives
GB0504324D0 (en)	2005-04-06	Bicyclic fused pyrimidine compounds
HK1130774A (en)	2010-01-08	Fused pyrimido compounds
HK1128470A (en)	2009-10-30	Bicyclic tetrahydropyrrole compounds
HK1128690A (en)	2009-11-06	Bicyclic tetrahydropyrrole compounds
GB0508681D0 (en)	2005-06-08	Antagonist
GB0506709D0 (en)	2005-05-11	Methods
GB0500607D0 (en)	2005-02-16	Methods